Identify the immunogenic epitope and produce monoclonal antibody
against COVID-19
In recently years, monoclonal antibody play a tremendous role in
therapeutic and diagnostics of many life-threatening infectious
disease.44 In the year of 2019, ZMapp antibody and the
antiviral agent remdesivir were dropped out due to unsuccessful
potential against Ebola virus. Later on, the monoclonal antibody MAb114
and REGN-EB3 showed more than 90% survivor rate of Ebola
patients.45 It was also indicated that antibodies
cocktail are more effective.46 Moreover, ZIKV-195, a
potently neutralizing human monoclonal antibody, has shown significant
therapeutic activity against Zika virus infection in a mouse
model.47
79.6% genomic sequence similarity and having the same human ACE2
receptor cells of SARS-CoV-1 and SARS-CoV-2 are the big scientific
evidence opportunities. The potent neutralizing monoclonal antibody
(CR3022, CR3014, m396, S230.15, R302, shown significant role in
neutralization against SARS-CoV-1.48-51
Table 2. Neutralizing monoclonal antibodies against SRAS-CoV-1
and their sensitive amino acid fragments